Improvements in survival after follicular lymphoma by race/ethnicity and socioeconomic status: A population-based study

Journal of Clinical Oncology

Volumn 27, Issue 18, 2009, Pages 3044-3051

  Keegan, Theresa H M ^a   McClure, Laura A ^a   Foran, James M ^a   Clarke, Christina A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

AFRICAN AMERICAN; AGED; ARTICLE; ASIAN; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CAUSE OF DEATH; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DISEASE FREE SURVIVAL; DISEASE SEVERITY; ETHNICITY; EUROPEAN AMERICAN; EVENT FREE SURVIVAL; FEMALE; FOLLICULAR LYMPHOMA; HISPANIC; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POPULATION BASED CASE CONTROL STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; RACE; RISK; SOCIAL STATUS; SURVIVAL RATE; TREND STUDY; UNITED STATES; VITAL STATISTICS; ABORIGINE; ETHNIC GROUP; NEGRO; SOCIOECONOMICS;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; CALIFORNIA; CONTINENTAL POPULATION GROUPS; ETHNIC GROUPS; FEMALE; HISPANIC AMERICANS; HUMANS; LYMPHOMA, FOLLICULAR; MALE; OCEANIC ANCESTRY GROUP; SOCIOECONOMIC FACTORS;

EID: 67649977040     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.8052     Document Type: Article

References (43)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma: The Non-Hodgkin's Lymphoma Classification Project. Blood 89:3909-3918, 1997
2. SEER*Stat Database: Incidence-SEER 17 Regs Limited-Use, Nov 2006 Sub (1973-2004 varying)-Linked To County Attributes-Total U.S., 1969-2004 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, Surveillance, Epidemiology, and End Results (SEER) Program, released April 2007, based on the November 2006 submission. http://www.seer.cancer.gov
3. SEER*Stat Database: Incidence-California, October 2007 (1988-2006), released October 2007: NCHS population estimates for 1990-2006, Benchmarked 1988-1989 DOF population estimates July 2007, California Cancer Registry, California Department of Health Services, Cancer Surveillance Section. http://www.ccrcal.org
4. Horning SJ: Follicular lymphoma: Have we made any progress? Ann Oncol 11:23-27, 2000
5. Fisher RI, LeBlanc M, Press OW, et al: New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 23:8447-8452, 2005
6. Horning SJ: Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 20:75-88, 1993
7. Arcaini L, Colombo N, Passamonti F, et al: Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment. Leuk Res 30:277-282, 2006
8. Liu Q, Fayad L, Cabanillas F, et al: Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 24:1582-1589, 2006
9. Sacchi S, Pozzi S, Marcheselli L, et al: Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients. Cancer 109:2077-2082, 2007
10. Swenson WT, Wooldridge JE, Lynch CF, et al: Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 23:5019-5026, 2005
11. National Comprehensive Cancer Network: Clinical practice guidelines in oncology: Non-Hodgkin's lymphoma (version 1.2005). http://www.nccn.org/ professionals/physician-gls/PDF/nhl.pdf
12. National Cancer Institute: Adult non-Hodgkin's lymphoma (PDQ): treatment (health professional version). http://www.cancer.gov/cancerinfo/pdq/treatment/ adult-non-hodgkins/healthprofessional
13. Pettengell R, Linch D: Position paper on the therapeutic use of rituximab in CD20-positive diffuse large B-cell non-Hodgkin's lymphoma. Br J Haematol 121:44-48, 2003
14. Herold M, Haas A, Srock S, et al: Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology Study. J Clin Oncol 25:1986-1992, 2007
15. Hiddemann W, Kneba M, Dreyling M, et al: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-3732, 2005
16. van Oers MH: Rituximab maintenance therapy: A step forward in follicular lymphoma. Haematologica 92:826-833, 2007
17. Cella DF, Orav EJ, Kornblith AB, et al: Socioeconomic status and cancer survival. J Clin Oncol 9:1500-1509, 1991
18. Boyd C, Zhang-Salomons JY, Groome PA, et al: Associations between community income and cancer survival in Ontario, Canada, and the United States. J Clin Oncol 17:2244-2255, 1999
19. Woods LM, Rachet B, Coleman MP: Origins of socio-economic inequalities in cancer survival: A review. Ann Oncol 17:5-19, 2006
20. Morton LM, Turner JJ, Cerhan JR, et al: Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 110:695-708, 2007
21. Yost K, Perkins C, Cohen R, et al: Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control 12:703-711, 2001
22. Clarke CA, Glaser SL, Keegan THM, et al: Neighborhood socioeconomic status and Hodgkin lymphoma incidence in California. Cancer Epidemiol Biomarkers Prev 14:1441-1447, 2005
23. Keegan TH, Glaser SL, Clarke CA, et al: Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: A population-based study. J Clin Oncol 23:7604-7613, 2005
24. Clarke CA, Glaser SL: Population-based surveillance of HIV-associated cancers: Utility of cancer registry data. J Acquir Immune Defic Syndr 36:1083-1091, 2004
25. Ward E, Halpern M, Schrag N, et al: Association of insurance with cancer care utilization and outcomes. CA Cancer J Clin 58:9-31, 2008
26. Sternberg AJ, Matutes E, Killick S, et al: Prolonged disease-free survival in relapsed/refractory lowgrade lymphoma treated with fludarabine: A report of four cases. Br J Haematol 102:532-534, 1998
27. Jabr FI: Acute tumor lysis syndrome induced by rituximab in diffuse large B-cell lymphoma. Int J Hematol 82:312-314, 2005
28. Cheung CW, Burton C, Smith P, et al: Central nervous system chemoprophylaxis in non-Hodgkin lymphoma: Current practice in the UK. Br J Haematol 131:193-200, 2005
29. Spectre G, Gural A, Amir G, et al: Central nervous system involvement in indolent lymphomas. Ann Oncol 16:450-454, 2005
30. Cheson BD: Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 13:2431-2448, 1995
31. Eversley R, Estrin D, Dibble S, et al: Post-treatment symptoms among ethnic minority breast cancer survivors. Oncol Nurs Forum 32:250-256, 2005
32. Tammemagi CM, Nerenz D, Neslund-Dudas C, et al: Comorbidity and survival disparities among black and white patients with breast cancer. JAMA 294:1765-1772, 2005
33. Ahluwalia IB, Mack KA, Murphy W, et al: State-specific prevalence of selected chronic disease-related characteristics: Behavioral Risk Factor Surveillance System, 2001. MMWR Surveill Summ 52:1-80, 2003
34. Krieger N: Overcoming the absence of socioeconomic data in medical records: Validation and application of a census-based methodology. Am J Public Health 82:703-710, 1992
35. Robert SA: Community-level socioeconomic status effects on adult health. J Health Soc Behav 39:18-37, 1998
36. Pickett KE, Pearl M: Multilevel analyses of neighbourhood socioeconomic context and health outcomes: A critical review. J Epidemiol Community Health 55:111-122, 2001
37. Varterasian ML, Graff JJ, Severson RK, et al: Non-Hodgkin's lymphoma: An analysis of the Metropolitan Detroit SEER database. Cancer Invest 18:303-308, 2000
38. Pulte D, Gondos A, Brenner H: Ongoing improvement in outcomes for patients diagnosed as having Non-Hodgkin lymphoma from the 1990s to the early 21st century. Arch Intern Med 168:469-476, 2008
39. Krol AD, le Cessie S, Snijder S, et al: Non-Hodgkin's lymphoma in the Netherlands: Results from a population-based registry. Leuk Lymphoma 44:451-458, 2003
40. Clarke CA, Glaser SL, Dorfman RF, et al: Expert review of non-Hodgkin's lymphomas in a population-based cancer registry: Reliability of diagnosis and subtype classifications. Cancer Epidemiol Biomarkers Prev 13:138-143, 2004
41. Clarke CA, Undurraga DM, Harasty PJ, et al: Changes in cancer registry coding for lymphoma subtypes: Reliability over time and relevance for surveillance and study. Cancer Epidemiol Biomarkers Prev 15:630-638, 2006
42. Solal-Céligny P, Roy P, Colombat P, et al: Follicular lymphoma international prognostic index. Blood 104:1258-1265, 2004
43. Cheson BD: Staging and evaluation of the patient with lymphoma. Hematol Oncol Clin North Am 22:825-837, 2008